Angelis Oncology files Form D for debt offering under Rule 506(b)
The San Francisco biotech reported a first sale date of July 10, 2026, and $400,000 raised from a single investor.
Angelis Oncology, Inc. filed a Form D notice with the Securities and Exchange Commission disclosing an exempt securities offering. The company is a Delaware corporation, incorporated within the last five years, in 2026.1 Its principal place of business is listed at 211 Belgrave Ave. in San Francisco, California.1
Daniel Santi is named as a related person, serving as President, Chief Executive Officer, Secretary, and Treasurer, and is identified as both an executive officer and director.1 The filing classifies the issuer's industry group as biotechnology within the health care category.1
The company reported deciding to decline disclosure of its revenue range or aggregate net asset value.1 The offering claims exemption under Rule 506(b).1
The filing is a new notice with a date of first sale listed as July 10, 2026.1 The company indicated it does not intend the offering to last more than one year.1 The type of security offered is listed as debt.1 The offering is not connected to a business combination transaction such as a merger or acquisition.1
The minimum investment accepted from any outside investor is listed as $0.1 The filing lists the total offering amount as indefinite, with total amount sold at $400,000, and total remaining to be sold also listed as indefinite.1 The company reported a total of one investor who has already invested in the offering.1
The filing lists sales commissions and finders' fees both at $0.1 The amount of proceeds proposed for use in payments to executive officers, directors, or promoters is listed as $0.1
The notice was signed by Daniel Santi as CEO of Angelis Oncology, Inc. on July 22, 2026.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.